February 5, 2016
In patients undergoing transcatheter aortic valve replacement with a next-generation valve, deeper implantation and prosthesis oversizing appear to be associated with a higher rate of new conduction abnormalities or need for permanent pacemaker implantation, according to study findings.
Researchers identified 244 consecutive patients (mean age, 81 years) with a logistic EuroSCORE of 16% who underwent TAVR with the next-generation valve (Sapien 3, Edwards Lifesciences) at Technische Universität München, Munich, Germany. After excluding patients with a previous pacemaker, atypical valvular anatomy and degenerated biological prosthesis, 208 patients were eligible for inclusion. TAVR was performed using the 23-mm Sapien 3 valve in 44% of patients while the 26-mm valve was used in 38% of patients and the 29-mm valve was used in 18% of patients.